{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:15:11Z","timestamp":1793502911781,"version":"4.5.0"},"reference-count":105,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.metabol.2014.09.002","type":"journal-article","created":{"date-parts":[[2014,9,28]],"date-time":"2014-09-28T16:15:23Z","timestamp":1411920923000},"page":"1480-1490","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":143,"title":["Type 2 diabetes mellitus and fracture risk"],"prefix":"10.1016","volume":"63","author":[{"given":"Anastasia D.","family":"Dede","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Symeon","family":"Tournis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismene","family":"Dontas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Trovas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2014.09.002_bb0005","series-title":"IDF Diabetes Atlas","year":"2013"},{"issue":"1","key":"10.1016\/j.metabol.2014.09.002_bb0010","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.diabres.2009.10.007","article-title":"Global estimates of the prevalence of diabetes for 2010 and 2030","volume":"87","author":"Shaw","year":"2010","journal-title":"Diabetes Res Clin Pract"},{"issue":"7","key":"10.1016\/j.metabol.2014.09.002_bb0015","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.2337\/dc06-0440","article-title":"Prospective study of diabetes and risk of hip fracture: the Nurses\u2019 Health Study","volume":"29","author":"Janghorbani","year":"2006","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.metabol.2014.09.002_bb0020","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1210\/jc.2006-0614","article-title":"Risk of fracture in women with type 2 diabetes: the Women\u2019s Health Initiative Observational Study","volume":"91","author":"Bonds","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.metabol.2014.09.002_bb0025","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1007\/s00198-005-1909-1","article-title":"Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam Study","volume":"16","author":"de Liefde","year":"2005","journal-title":"Osteoporos Int"},{"issue":"8","key":"10.1016\/j.metabol.2014.09.002_bb0030","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1359\/jbmr.080323","article-title":"Fracture risk in type 2 diabetes: update of a population-based study","volume":"23","author":"Melton","year":"2008","journal-title":"J Bone Miner Res"},{"issue":"7","key":"10.1016\/j.metabol.2014.09.002_bb0035","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1007\/s00125-005-1786-3","article-title":"Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk","volume":"48","author":"Vestergaard","year":"2005","journal-title":"Diabetologia"},{"issue":"5","key":"10.1016\/j.metabol.2014.09.002_bb0040","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/aje\/kwm106","article-title":"Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture","volume":"166","author":"Janghorbani","year":"2007","journal-title":"Am J Epidemiol"},{"issue":"4","key":"10.1016\/j.metabol.2014.09.002_bb0045","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1359\/jbmr.081207","article-title":"Diabetic patients have an increased risk of vertebral fractures independent of BMD or diabetic complications","volume":"24","author":"Yamamoto","year":"2009","journal-title":"J Bone Miner Res"},{"issue":"7","key":"10.1016\/j.metabol.2014.09.002_bb0050","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.2337\/diacare.24.7.1198","article-title":"Diabetes and risk of fracture: the Blue Mountains Eye Study","volume":"24","author":"Ivers","year":"2001","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.metabol.2014.09.002_bb0055","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/j.bone.2007.02.021","article-title":"Biphasic fracture risk in diabetes: a population-based study","volume":"40","author":"Leslie","year":"2007","journal-title":"Bone"},{"issue":"10","key":"10.1016\/j.metabol.2014.09.002_bb0060","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.2337\/diacare.25.10.1749","article-title":"Older women with diabetes have a higher risk of falls: a prospective study","volume":"25","author":"Schwartz","year":"2002","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.metabol.2014.09.002_bb0065","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.2337\/diacare.23.9.1272","article-title":"Diabetes and physical disability among older U.S. adults","volume":"23","author":"Gregg","year":"2000","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.metabol.2014.09.002_bb0070","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1093\/oxfordjournals.aje.a116871","article-title":"Risk factors for injurious falls leading to hospitalization or death in a cohort of 19,500 adults","volume":"138","author":"Malmivaara","year":"1993","journal-title":"Am J Epidemiol"},{"issue":"7","key":"10.1016\/j.metabol.2014.09.002_bb0075","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1463-1326.2012.01583.x","article-title":"Association between hypoglycaemic events and fall-related fractures in Medicare-covered patients with type 2 diabetes","volume":"14","author":"Johnston","year":"2012","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.metabol.2014.09.002_bb0080","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00223-008-9195-5","article-title":"Diabetes and its complications and their relationship with risk of fractures in type 1 and 2 diabetes","volume":"84","author":"Vestergaard","year":"2009","journal-title":"Calcif Tissue Int"},{"issue":"6","key":"10.1016\/j.metabol.2014.09.002_bb0085","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.2337\/dc12-1188","article-title":"High bone mineral density and fracture risk in type 2 diabetes as skeletal complications of inadequate glucose control: the Rotterdam Study","volume":"36","author":"Oei","year":"2013","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.metabol.2014.09.002_bb0090","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.2337\/dc11-2184","article-title":"Intensive glycemic control is not associated with fractures or falls in the ACCORD randomized trial","volume":"35","author":"Schwartz","year":"2012","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.metabol.2014.09.002_bb0095","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1002\/jbmr.73","article-title":"Microindentation for in vivo measurement of bone tissue mechanical properties in humans","volume":"25","author":"Diez-Perez","year":"2010","journal-title":"J Bone Miner Res"},{"issue":"12","key":"10.1016\/j.metabol.2014.09.002_bb0100","doi-asserted-by":"crossref","first-page":"e82733","DOI":"10.1371\/journal.pone.0082733","article-title":"Glycated haemoglobin is inversely related to serum vitamin D levels in type 2 diabetic patients","volume":"8","author":"Zoppini","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.metabol.2014.09.002_bb0105","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1507\/endocrj.EJ12-0269","article-title":"The association of serum 25-hydroxyvitamin D and vertebral fractures in patients with type 2 diabetes","volume":"60","author":"Kim","year":"2013","journal-title":"Endocr J"},{"issue":"5","key":"10.1016\/j.metabol.2014.09.002_bb0110","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s10654-012-9674-x","article-title":"Association between bone mineral density and type 2 diabetes mellitus: a meta-analysis of observational studies","volume":"27","author":"Ma","year":"2012","journal-title":"Eur J Epidemiol"},{"issue":"7","key":"10.1016\/j.metabol.2014.09.002_bb0115","doi-asserted-by":"crossref","first-page":"775","DOI":"10.2337\/diab.44.7.775","article-title":"Bone loss and bone turnover in diabetes","volume":"44","author":"Krakauer","year":"1995","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.metabol.2014.09.002_bb0120","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1359\/JBMR.041219","article-title":"Diabetes and bone loss at the hip in older black and white adults","volume":"20","author":"Schwartz","year":"2005","journal-title":"J Bone Miner Res"},{"issue":"10","key":"10.1016\/j.metabol.2014.09.002_bb0125","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.2337\/dc14-0762","article-title":"Bone loss at four-year follow-up in type 2 diabetes","volume":"37","author":"Lipkin","year":"2014","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.metabol.2014.09.002_bb0130","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0168-8227(94)90126-0","article-title":"Osteopenia associated with non-insulin-dependent diabetes mellitus: what are the causes?","volume":"23","author":"Gregorio","year":"1994","journal-title":"Diabetes Res Clin Pract"},{"issue":"2","key":"10.1016\/j.metabol.2014.09.002_bb0135","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s00198-011-1595-0","article-title":"Bone structure and turnover in type 2 diabetes mellitus","volume":"23","author":"Shu","year":"2012","journal-title":"Osteoporos Int"},{"issue":"4","key":"10.1016\/j.metabol.2014.09.002_bb0140","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/jbmr.2106","article-title":"In Vivo assessment of bone quality in postmenopausal women with type 2 diabetes","volume":"29","author":"Farr","year":"2014","journal-title":"J Bone Miner Res"},{"issue":"6","key":"10.1016\/j.metabol.2014.09.002_bb0145","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1007\/s00198-014-2676-7","article-title":"Biochemical markers of bone turnover in diabetes patients-a meta-analysis, and a methodological study on the effects of glucose on bone markers","volume":"25","author":"Starup-Linde","year":"2014","journal-title":"Osteoporos Int"},{"issue":"1","key":"10.1016\/j.metabol.2014.09.002_bb0150","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1210\/jc.2011-2186","article-title":"Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus","volume":"97","author":"Garc\u00eda-Mart\u00edn","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.metabol.2014.09.002_bb0155","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.bone.2013.06.029","article-title":"Increased serum sclerostin and decreased serum IGF-1 are associated with vertebral fractures among postmenopausal women with type-2 diabetes","volume":"56","author":"Ardawi","year":"2013","journal-title":"Bone"},{"issue":"5","key":"10.1016\/j.metabol.2014.09.002_bb0160","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1002\/jbmr.2210","article-title":"a review of rodent models of type 2 diabetic skeletal fragility","volume":"29","author":"Fajardo","year":"2014","journal-title":"J Bone Miner Res"},{"issue":"2","key":"10.1016\/j.metabol.2014.09.002_bb0165","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1359\/jbmr.090725","article-title":"Bone mass and strength in older men with type 2 diabetes: the Osteoporotic Fractures in Men Study","volume":"25","author":"Petit","year":"2010","journal-title":"J Bone Miner Res"},{"issue":"6","key":"10.1016\/j.metabol.2014.09.002_bb0170","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.2337\/db05-1183","article-title":"Decreased muscle strength and quality in older adults with type 2 diabetes: the health, aging, and body composition study","volume":"55","author":"Park","year":"2006","journal-title":"Diabetes"},{"issue":"11","key":"10.1016\/j.metabol.2014.09.002_bb0175","doi-asserted-by":"crossref","first-page":"5045","DOI":"10.1210\/jc.2010-0226","article-title":"High-resolution peripheral quantitative computed tomographic imaging of cortical and trabecular bone microarchitecture in patients with type 2 diabetes mellitus","volume":"95","author":"Burghardt","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.metabol.2014.09.002_bb0180","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/jbmr.1763","article-title":"Increased cortical porosity in type 2 diabetic postmenopausal women with fragility fractures","volume":"28","author":"Patsch","year":"2013","journal-title":"J Bone Miner Res"},{"issue":"1","key":"10.1016\/j.metabol.2014.09.002_bb0185","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1210\/jc.2011-1883","article-title":"Diabetes and femoral neck strength: findings from the Hip Strength Across the Menopausal Transition Study","volume":"97","author":"Ishii","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.metabol.2014.09.002_bb0190","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/j.metabol.2012.05.010","article-title":"Hip geometry in diabetic women: implications for fracture risk","volume":"61","author":"Garg","year":"2012","journal-title":"Metabolism"},{"issue":"11","key":"10.1016\/j.metabol.2014.09.002_bb0195","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1002\/jbmr.499","article-title":"Bone microarchitecture assessed by TBS predicts osteoporotic fractures independent of bone density: the Manitoba study","volume":"26","author":"Hans","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"2","key":"10.1016\/j.metabol.2014.09.002_bb0200","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1210\/jc.2012-3118","article-title":"Manitoba Bone Density Program. TBS (trabecular bone score) and diabetes-related fracture risk","volume":"98","author":"Leslie","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.metabol.2014.09.002_bb0205","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1007\/s00198-014-2704-7","article-title":"Bone quality assessment in type 2 diabetes mellitus","volume":"25","author":"Dhaliwal","year":"2014","journal-title":"Osteoporos Int"},{"issue":"5","key":"10.1016\/j.metabol.2014.09.002_bb0210","doi-asserted-by":"crossref","first-page":"054303","DOI":"10.1063\/1.3127602","article-title":"The tissue diagnostic instrument","volume":"80","author":"Hansma","year":"2009","journal-title":"Rev Sci Instrum"},{"issue":"1","key":"10.1016\/j.metabol.2014.09.002_bb0215","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.bone.2013.01.032","article-title":"Bone mineralization is elevated and less heterogeneous in adults with type 2 diabetes and osteoarthritis compared to controls with osteoarthritis alone","volume":"54","author":"Pritchard","year":"2013","journal-title":"Bone"},{"issue":"4","key":"10.1016\/j.metabol.2014.09.002_bb0220","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.bone.2006.12.056","article-title":"Effects of non-enzymatic glycation on cancellous bone fragility","volume":"40","author":"Tang","year":"2007","journal-title":"Bone"},{"issue":"2","key":"10.1016\/j.metabol.2014.09.002_bb0225","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S8756-3282(00)00434-8","article-title":"Influence of nonenzymatic glycation on biomechanical properties of cortical bone","volume":"28","author":"Vashishth","year":"2001","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.metabol.2014.09.002_bb0230","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.bone.2009.09.003","article-title":"Non-enzymatic glycation alters microdamage formation in human cancellous bone","volume":"46","author":"Tang","year":"2010","journal-title":"Bone"},{"issue":"4","key":"10.1016\/j.metabol.2014.09.002_bb0235","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s00223-012-9641-2","article-title":"Advanced glycation end products (AGEs), but not high glucose, inhibit the osteoblastic differentiation of mouse stromal ST2 cells through the suppression of osterix expression, and inhibit cell growth and increasing cell apoptosis","volume":"91","author":"Okazaki","year":"2012","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.metabol.2014.09.002_bb0240","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1196\/annals.1433.044","article-title":"Pentosidine effects on human osteoblasts in vitro","volume":"1126","author":"Sanguineti","year":"2008","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"10.1016\/j.metabol.2014.09.002_bb0245","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.bone.2006.09.011","article-title":"Advanced glycation end products stimulate osteoblast apoptosis via the MAP kinase and cytosolic apoptotic pathways","volume":"40","author":"Alikhani","year":"2007","journal-title":"Bone"},{"issue":"8","key":"10.1016\/j.metabol.2014.09.002_bb0250","doi-asserted-by":"crossref","first-page":"5691","DOI":"10.1074\/jbc.M610536200","article-title":"Non-enzymatic glycation of bone collagen modifies osteoclastic activity and differentiation","volume":"282","author":"Valcourt","year":"2007","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.metabol.2014.09.002_bb0255","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.bone.2011.04.009","article-title":"In situ accumulation of advanced glycation endproducts (AGEs) in bone matrix and its correlation with osteoclastic bone resorption","volume":"49","author":"Dong","year":"2011","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.metabol.2014.09.002_bb0260","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.bone.2009.10.012","article-title":"HO-1 expression increases mesenchymal stem cell-derived osteoblasts but decreases adipocyte lineage","volume":"46","author":"Vanella","year":"2010","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.metabol.2014.09.002_bb0265","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S8756-3282(97)00220-2","article-title":"Growth-inhibitory effect of a high glucose concentration on osteoblast-like cells","volume":"22","author":"Terada","year":"1998","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.metabol.2014.09.002_bb0270","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/15216540601156188","article-title":"Effects of reactive oxygen species (ROS) on antioxidant system and osteoblastic differentiation in MC3T3-E1 cells","volume":"59","author":"Arai","year":"2007","journal-title":"IUBMB Life"},{"issue":"5","key":"10.1016\/j.metabol.2014.09.002_bb0275","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1016\/j.bone.2006.12.057","article-title":"Histomorphometric analysis of diabetic osteopenia in streptozotocin-induced diabetic mice: a possible role of oxidative stress","volume":"40","author":"Hamada","year":"2007","journal-title":"Bone"},{"key":"10.1016\/j.metabol.2014.09.002_bb0280","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1196\/annals.1333.082","article-title":"Advanced glycation end products and bone loss during aging","volume":"1043","author":"Odetti","year":"2005","journal-title":"Ann N Y Acad Sci"},{"issue":"5","key":"10.1016\/j.metabol.2014.09.002_bb0285","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.bone.2006.05.013","article-title":"Contribution of the advanced glycation end product pentosidine and of maturation of type I collagen to compressive biomechanical properties of human lumbar vertebrae","volume":"39","author":"Viguet-Carrin","year":"2006","journal-title":"Bone"},{"issue":"7","key":"10.1016\/j.metabol.2014.09.002_bb0290","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1007\/s00198-006-0087-0","article-title":"Reductions in degree of mineralization and enzymatic collagen cross-links and increases in glycation-induced pentosidine in the femoral neck cortex in cases of femoral neck fracture","volume":"17","author":"Saito","year":"2006","journal-title":"Osteoporos Int"},{"issue":"11","key":"10.1016\/j.metabol.2014.09.002_bb0295","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1002\/jbmr.467","article-title":"Urinary pentosidine improves risk classification using fracture risk assessment tools for postmenopausal women","volume":"26","author":"Tanaka","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"3","key":"10.1016\/j.metabol.2014.09.002_bb0300","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1210\/jc.2007-1270","article-title":"Serum pentosidine levels are positively associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes","volume":"93","author":"Yamamoto","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.metabol.2014.09.002_bb0305","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1210\/jc.2008-2498","article-title":"Pentosidine and increased fracture risk in older adults with type 2 diabetes","volume":"94","author":"Schwartz","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.metabol.2014.09.002_bb0310","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1210\/endo.143.6.8834","article-title":"Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation","volume":"143","author":"Lecka-Czernik","year":"2002","journal-title":"Endocrinology"},{"issue":"8","key":"10.1016\/j.metabol.2014.09.002_bb0315","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/j.1464-5491.2010.03048.x","article-title":"Thiazolidinediones induce osteocyte apoptosis and increase sclerostin expression","volume":"27","author":"Mabilleau","year":"2010","journal-title":"Diabet Med"},{"issue":"1","key":"10.1016\/j.metabol.2014.09.002_bb0320","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1677\/joe.1.05723","article-title":"Rosiglitazone impacts negatively on bone by promoting osteoblast\/osteocyte apoptosis","volume":"183","author":"Soroc\u00e9anu","year":"2004","journal-title":"J Endocrinol"},{"issue":"9","key":"10.1016\/j.metabol.2014.09.002_bb0325","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1210\/jc.2005-2226","article-title":"Thiazolidinedione use and bone loss in older diabetic adults","volume":"91","author":"Schwartz","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.metabol.2014.09.002_bb0330","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1210\/jc.2007-2249","article-title":"Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial","volume":"93","author":"Glintborg","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.metabol.2014.09.002_bb0335","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.2337\/dc06-2606","article-title":"Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men","volume":"30","author":"Yaturu","year":"2007","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.metabol.2014.09.002_bb0340","doi-asserted-by":"crossref","first-page":"4560","DOI":"10.1210\/jc.2009-2638","article-title":"Thiazolidinediones and fractures: evidence from translating research into action for diabetes","volume":"95","author":"Bilik","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"15","key":"10.1016\/j.metabol.2014.09.002_bb0345","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1001\/archinternmed.2009.214","article-title":"Thiazolidinediones and fractures in men and women","volume":"169","author":"Dormuth","year":"2009","journal-title":"Arch Intern Med"},{"issue":"5","key":"10.1016\/j.metabol.2014.09.002_bb0350","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/s00774-010-0160-9","article-title":"Relationship between treatments with insulin and oral hypoglycemic agents versus the presence of vertebral fractures in type 2 diabetes mellitus","volume":"28","author":"Kanazawa","year":"2010","journal-title":"J Bone Miner Metab"},{"issue":"3","key":"10.1016\/j.metabol.2014.09.002_bb0355","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.metabol.2009.08.003","article-title":"Glimepiride induces proliferation and differentiation of rat osteoblasts via the PI3-kinase\/Akt pathway","volume":"59","author":"Ma","year":"2010","journal-title":"Metabolism"},{"issue":"1\u20132","key":"10.1016\/j.metabol.2014.09.002_bb0360","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejphar.2006.02.030","article-title":"Osteogenic actions of the anti-diabetic drug metformin on osteoblasts in culture","volume":"536","author":"Cortizo","year":"2006","journal-title":"Eur J Pharmacol"},{"issue":"10","key":"10.1016\/j.metabol.2014.09.002_bb0365","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1002\/jcb.23206","article-title":"Metformin stimulates osteoprotegerin and reduces RANKL expression in osteoblasts and ovariectomized rats","volume":"112","author":"Mai","year":"2011","journal-title":"J Cell Biochem"},{"issue":"3","key":"10.1016\/j.metabol.2014.09.002_bb0370","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.ejphar.2011.07.033","article-title":"Metformin prevents anti-osteogenic in vivo and ex vivo effects of rosiglitazone in rats","volume":"668","author":"Sedlinsky","year":"2011","journal-title":"Eur J Pharmacol"},{"issue":"11","key":"10.1016\/j.metabol.2014.09.002_bb0375","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1111\/j.1463-1326.2011.01461.x","volume":"13","author":"Borges","year":"2011","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"10.1016\/j.metabol.2014.09.002_bb0380","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1055\/s-2007-992786","article-title":"Metformin reverts deleterious effects of advanced glycation end-products (AGEs) on osteoblastic cells","volume":"116","author":"Schurman","year":"2008","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"2","key":"10.1016\/j.metabol.2014.09.002_bb0385","doi-asserted-by":"crossref","first-page":"214","DOI":"10.14310\/horm.2002.1405","article-title":"Incretins and bone: evolving concepts in nutrient-dependent regulation of bone turnover","volume":"12","author":"Yavropoulou","year":"2013","journal-title":"Hormones (Athens)"},{"issue":"4","key":"10.1016\/j.metabol.2014.09.002_bb0390","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1463-1326.2010.01355.x","article-title":"Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetes","volume":"13","author":"Bunck","year":"2011","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"10.1016\/j.metabol.2014.09.002_bb0395","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/1753-0407.12102","article-title":"Use of glucagon-like peptide-1 receptor agonists and bone fractures: a meta-analysis of randomized clinical trials","volume":"6","author":"Mabilleau","year":"2014","journal-title":"J Diabetes"},{"issue":"3","key":"10.1016\/j.metabol.2014.09.002_bb0400","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1210\/endo.141.3.7366","article-title":"Osteoblast-derived cells express functional glucose-dependent insulinotropic peptide receptors","volume":"141","author":"Bollag","year":"2000","journal-title":"Endocrinology"},{"issue":"1","key":"10.1016\/j.metabol.2014.09.002_bb0405","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/MED.0b013e3283344a05","article-title":"Gastrointestinal peptides and bone health","volume":"17","author":"Wong","year":"2010","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"3","key":"10.1016\/j.metabol.2014.09.002_bb0410","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.bone.2006.09.025","article-title":"Disassociation of bone resorption and formation by GLP-2: a 14-day study in healthy postmenopausal women","volume":"40","author":"Henriksen","year":"2007","journal-title":"Bone"},{"issue":"5","key":"10.1016\/j.metabol.2014.09.002_bb0415","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.bone.2009.07.008","article-title":"Four-month treatment with GLP-2 significantly increases hip BMD: a randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD","volume":"45","author":"Henriksen","year":"2009","journal-title":"Bone"},{"issue":"2","key":"10.1016\/j.metabol.2014.09.002_bb0420","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1210\/en.2010-1098","article-title":"Differential effects of PPAR-{gamma} activation versus chemical or genetic reduction of DPP-4 activity on bone quality in mice","volume":"152","author":"Kyle","year":"2011","journal-title":"Endocrinology"},{"key":"10.1016\/j.metabol.2014.09.002_bb0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2014.07.030","article-title":"Use of dipeptidyl peptidase-4 inhibitors for type 2 diabetes mellitus and risk of fracture","author":"Driessen","year":"2014","journal-title":"Bone"},{"issue":"11","key":"10.1016\/j.metabol.2014.09.002_bb0430","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.2337\/dc11-1099","article-title":"Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials","volume":"34","author":"Monami","year":"2011","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.metabol.2014.09.002_bb0435","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/j.1463-1326.2012.01630.x","article-title":"Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin","volume":"14","author":"Ljunggren","year":"2012","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"10.1016\/j.metabol.2014.09.002_bb0440","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1055\/s-2007-978777","article-title":"The effect of pramlintide (amylin analogue) treatment on bone metabolism and bone density in patients with type 1 diabetes mellitus","volume":"31","author":"Borm","year":"1999","journal-title":"Horm Metab Res"},{"issue":"21","key":"10.1016\/j.metabol.2014.09.002_bb0445","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1001\/jama.2011.715","article-title":"Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes","volume":"305","author":"Schwartz","year":"2011","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.metabol.2014.09.002_bb0450","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/jbmr.556","article-title":"FRAX underestimates fracture risk in patients with diabetes","volume":"27","author":"Giangregorio","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2014.09.002_bb0455","doi-asserted-by":"crossref","DOI":"10.1007\/s00198-014-2822-2","article-title":"Does diabetes modify the effect of FRAX risk factors for predicting major osteoporotic and hip fracture?","author":"Leslie","year":"2014","journal-title":"Osteoporos Int"},{"issue":"1","key":"10.1016\/j.metabol.2014.09.002_bb0460","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00198-012-2074-y","volume":"24","author":"Kanis","year":"2013","journal-title":"Osteoporos Int"},{"issue":"3","key":"10.1016\/j.metabol.2014.09.002_bb0465","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00223-010-9450-4","article-title":"Are antiresorptive drugs effective against fractures in patients with diabetes?","volume":"88","author":"Vestergaard","year":"2011","journal-title":"Calcif Tissue Int"},{"issue":"5","key":"10.1016\/j.metabol.2014.09.002_bb0470","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1359\/jbmr.040211","article-title":"Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study","volume":"19","author":"Johnell","year":"2004","journal-title":"J Bone Miner Res"},{"issue":"7","key":"10.1016\/j.metabol.2014.09.002_bb0475","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.2337\/diacare.27.7.1547","article-title":"Fracture intervention trial. Effect of alendronate on bone mineral density and biochemical markers of bone turnover in type 2 diabetic women: the fracture intervention trial","volume":"27","author":"Keegan","year":"2004","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.metabol.2014.09.002_bb0480","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1359\/jbmr.070904","article-title":"Effects of raloxifene on fracture risk in postmenopausal women: the Raloxifene Use for the Heart Trial","volume":"23","author":"Ensrud","year":"2008","journal-title":"J Bone Miner Res"},{"issue":"6","key":"10.1016\/j.metabol.2014.09.002_bb0485","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1002\/jbmr.1865","article-title":"Effects of antiresorptive therapies on glucose metabolism: results from the FIT, HORIZON-PFT, and FREEDOM trials","volume":"28","author":"Schwartz","year":"2013","journal-title":"J Bone Miner Res"},{"issue":"6","key":"10.1016\/j.metabol.2014.09.002_bb0490","doi-asserted-by":"crossref","first-page":"653","DOI":"10.3109\/17453674.2012.747054","article-title":"Patient-related risk factors for fracture-healing complications in the United Kingdom General Practice Research Database","volume":"83","author":"Hernandez","year":"2012","journal-title":"Acta Orthop"},{"issue":"2","key":"10.1016\/j.metabol.2014.09.002_bb0495","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3113\/FAI.2011.0120","article-title":"Outcomes of ankle fractures in patients with uncomplicated versus complicated diabetes","volume":"32","author":"Wukich","year":"2011","journal-title":"Foot Ankle Int"},{"issue":"2","key":"10.1016\/j.metabol.2014.09.002_bb0500","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1053\/j.jfas.2012.11.012","article-title":"Factors associated with nonunion, delayed union, and malunion in foot and ankle surgery in diabetic patients","volume":"52","author":"Shibuya","year":"2013","journal-title":"J Foot Ankle Surg"},{"issue":"8","key":"10.1016\/j.metabol.2014.09.002_bb0505","first-page":"1712","article-title":"The impact of diabetes on patient outcomes after ankle fracture","volume":"87","author":"Ganesh","year":"2005","journal-title":"J Bone Joint Surg Am"},{"issue":"5","key":"10.1016\/j.metabol.2014.09.002_bb0510","doi-asserted-by":"crossref","first-page":"813","DOI":"10.3760\/cma.j.issn.0366-6999.20122712","article-title":"Impact of diabetes on the prognosis of hip fracture: a cohort study in the Chinese population","volume":"126","author":"Wang","year":"2013","journal-title":"Chin Med J (Engl)"},{"issue":"7","key":"10.1016\/j.metabol.2014.09.002_bb0515","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1600-0501.2010.01923.x","article-title":"The effect of diabetes mellitus on osseous healing","volume":"21","author":"Retzepi","year":"2010","journal-title":"Clin Oral Implants Res"},{"issue":"1","key":"10.1016\/j.metabol.2014.09.002_bb0520","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1210\/jc.2011-2098","article-title":"Endocrine Society. Management of hyperglycemia in hospitalized patients in non-critical care setting: an endocrine society clinical practice guideline","volume":"97","author":"Umpierrez","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2014.09.002_bb0525","article-title":"Peri-implant evaluation in type 2 diabetes mellitus patients: a 3-year study","author":"G\u00f3mez-Moreno","year":"2014","journal-title":"Clin Oral Implants Res"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049514002844?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049514002844?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T04:05:53Z","timestamp":1758427553000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049514002844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":105,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S0026049514002844"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2014.09.002","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Type 2 diabetes mellitus and fracture risk","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2014.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}